Announcements Trials
Browse Landscape

Phase

Phase 2 20Phase 1 12Phase 3 7Phase 1/2 2Phase NA 1Phase 2/3 1

Status

Recruiting 11Unknown 7Not yet recruiting 4Completed 2Active not recruiting 2Withdrawn 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 1Gynecologic 1Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Advanced Solid Tumor 1

Interventions

Cyclophosphamide 142Gemcitabine 129Paclitaxel 125Radiotherapy 119Cisplatin 111Carboplatin 111pembrolizumab 109Nivolumab 106Docetaxel 90Rituximab 86Lenalidomide 77Dexamethasone 76Cytarabine 69Bevacizumab 64Fluorouracil 63Etoposide 63Oxaliplatin 62Filgrastim 59Peripheral Blood Stem Cell Transplantation 58Everolimus 58Capecitabine 58fludarabine phosphate 57Doxorubicin 56Temozolomide 55Prednisone 54Irinotecan 53Cetuximab 50fludarabine 48Ipilimumab 48Erlotinib Hydrochloride 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Completed × sintilimab × Clear all
NCT05383482 2025-11-17

Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1

Laekna Limited

Phase 1/2 Completed
22 enrolled
GastrointestinalGynecologic

Uterine Cervical Neoplasms, Esophageal Neoplasms, Endometrial Neoplasms

NCT03903705 2025-04-06

: A Phase Ib/II Study To Evaluate Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid Tumors

Hutchmed

Phase 1/2 Completed
348 enrolled
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡